

Dronabinol as an Adjunct for Reducing Pain

NCT06454669

Status	RECRUITING
Phase	Phase 2
Sponsor	Christopher D. Verrico
Enrollment	75 participants

Key Eligibility Criteria

Inclusion (23)

- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Ability to take oral medication per protocol.
- Male or female, aged 18-64 years.
- Has chronic low back pain (i.e., in the space between the lower posterior margin of the rib cage and the horizontal gluteal fold) that has persisted at least 3 months and has resulted in pain on at least half the days in the past 6 months (Items 1 & 2 from the Research Standards for Chronic Low-Back Pain (RScLBP) assessment).

... and 18 more (see full listing online)

Exclusion (24)

- Current and unwilling to stop use of cannabis/marijuana and any other cannabinoids, including over the counter CBD products.
- Known allergic reactions to cannabis, CBD, THC, or components of the study interventions.
- Have Blood Urea Nitrogen or Creatinine levels outside the normal range, or other clinically significant laboratory abnormalities.
- Current use of Antiepileptic drugs.
- Current use of barbiturates, benzodiazepines, ethanol, lithium, buspirone, muscle relaxants

... and 19 more (see full listing online)

Locations (1 total)

Michael E Debaakey VA Medical Center, Houston, Texas, United States